Hy Phan, MD
Psychiatry · San Diego, CANPI 1144373408
Payments from drug & device makers
Across 269 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$785
- AbbVie$723
- Neurocrine Biosciences, Inc.$638
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$626
- Alkermes, Inc.$556
- Otsuka America Pharmaceutical, Inc.$505
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,47593%
- Education$3957%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 27 | $785 |
| AbbVie(2 entities) | 37 | $723 |
| Neurocrine Biosciences, Inc. | 28 | $638 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $626 |
| Alkermes, Inc. | 27 | $556 |
| Otsuka America Pharmaceutical, Inc. | 25 | $505 |
| Johnson & Johnson | 21 | $467 |
| Vanda Pharmaceuticals Inc. | 19 | $399 |
| Indivior Inc. | 14 | $325 |
| Sunovion Pharmaceuticals Inc. | 18 | $279 |
| Lundbeck LLC | 11 | $214 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Tempus AI, Inc | 2 | $60 |
| Eisai Inc. | 3 | $43 |
| Merck | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$5,869 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 56 | $395,332 |
| Austedo XrDeutetrabenazine | 44 | $236,667 |
| VraylarCariprazine Hcl | 170 | $164,400 |
| Invega TrinzaPaliperidone Palmitate | 19 | $152,420 |
| AustedoDeutetrabenazine | 35 | $124,279 |
| RexultiBrexpiprazole | 94 | $108,390 |
| Lurasidone Hcl | 187 | $60,869 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $52,222 |
| CaplytaLumateperone Tosylate | 37 | $43,148 |
| TrintellixVortioxetine Hydrobromide | 73 | $35,591 |
| Risperidone ErRisperidone Microspheres | 25 | $25,415 |
| FanaptIloperidone | 13 | $16,190 |
| InvegaPaliperidone | 29 | $13,301 |
| Chlorpromazine Hcl | 70 | $10,809 |
| LexaproEscitalopram Oxalate | 11 | $7,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $638 | $395,33256 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $785 | $360,94779 claims |
| AbbVieVraylar, Lexapro | $723 | $171,859181 claims |
| Johnson & JohnsonInvega Trinza, Invega | $467 | $165,72248 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $505 | $108,39094 claims |
| Alkermes, Inc.Lybalvi | $556 | $52,22227 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $626 | $43,14837 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $82 | $35,59173 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $399 | $16,19013 claims |
| Eisai Inc.Dayvigo | $43 | $3,87411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Eric ChavezSan Diego$15.5M
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.